Investor directory

Alcazar Capital

Alcazar Capital Limited is a private equity firm based in Dubai, specializing in buyout investments across various sectors, including telecom infrastructure, fintech, energy, healthcare, logistics, real estate, and education. The firm focuses on emerging markets in Sub-Saharan Africa, the MENA region, South East Asia, India, and the Commonwealth of Independent States, while also investing in developed markets. With a portfolio that exceeds $1.0 billion in assets under management, Alcazar Capital typically seeks to acquire a majority stake in its portfolio companies. Additionally, the firm offers financial advisory services to smaller organizations and manages client-focused investment portfolios. Established in 2007, Alcazar Capital employs a combination of fundamental and quantitative analysis, along with in-house research, to guide its investment strategies.
http://www.alcazar-capital.com
https://crunchbase.com/organization/alcazar-capital
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=39033281
https://www.privateequityinternational.com/database/#/profile?id=12975

Charbel Abou-Jaoude

Chief Executive Officer and President

Yaroslav Afonin

Associate

Maissan Almaskati

Managing Partner

Toni Azar

Principal

Mara D'Urso

Vice President

Rami Kilajian

Managing Partner

Srivats Kumar

Vice President of Private Equity

Nabil Mahraoui

Principal of Private Equity Investments and Chief Financial Officer

Patrick Tangney

Partner

1 past transactions

Emerald Cloud Lab

Series C in 2019
Emerald was founded in 2010 by two scientists and life-long friends from Philadelphia with a singular vision of how a biotechnology company should run. Frustrated by the continual deceleration of innovation and the exponentially increasing R&D costs in the pharmaceutical sector, Emerald models itself after the legendary start-up companies of the mid-20th century that built the core technologies underlying the meteoric rise of the semiconductor industry. The team places as much focus on building tools around how scientific research is conducted as they do on their proprietary anti-viral therapies. In this way, Emerald is striving to bring a Moore’s law-like acceleration to life sciences innovation.